Press Releases

Date Title and Summary Additional Formats
Toggle Summary Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2018
Reports Net Revenues of $89.7 Million for the Three Months Ended December 31, 2018 RANCHO CUCAMONGA, Calif. , March 12, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months and full year ended December 31,
View HTML
Toggle Summary Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 12, 2019
RANCHO CUCAMONGA, Calif. , March 07, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its fourth quarter of 2018 ended December 31, 2018 , after the market closes on Tuesday, March 12, 2019 , and will hold a conference call
View HTML
Toggle Summary Amphastar Pharmaceuticals, Inc. Announces Launch of Primatene® MIST to Nationwide Retail Pharmacies
RANCHO CUCAMONGA, Calif. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. , (NASDAQ: AMPH) announced today that Primatene ® MIST has been launched. Primatene ® MIST is an epinephrine inhalation aerosol bronchodilator suspension, which is the only FDA -approved metered dose
View HTML
Toggle Summary Amphastar Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference 2018
RANCHO CUCAMONGA, Calif. , Nov. 20, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters , CFO will be presenting at the 30 th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28, 2018 at 1:30 p.m. Eastern Time , New York, NY .
View HTML
Toggle Summary Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference 2018
RANCHO CUCAMONGA, Calif. , Nov. 09, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell , President, and Bill Peters , CFO will be presenting at the Jefferies London Healthcare Conference on Wednesday, November 14, 2018 at 2:00 p.m.
View HTML
Toggle Summary Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2018
Reports Net Revenues of $75.5 Million for the Three Months Ended September 30, 2018 RANCHO CUCAMONGA, Calif. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended September 30, 2018 .
View HTML
Toggle Summary Amphastar Pharmaceuticals, Inc. Announces Reintroduction of Primatene® MIST
Primatene ® MIST fills unmet medical need as the only FDA approved over-the-counter asthma inhaler Primatene Mist RANCHO CUCAMONGA, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. , (NASDAQ: AMPH) announced today that the U.S.
View HTML
Toggle Summary Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2018
RANCHO CUCAMONGA, Calif. , Nov. 02, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its Third quarter of 2018 ended September 30, 2018 , after the market closes on Wednesday, November 8, 2018 , and will hold a conference
View HTML
Toggle Summary Amphastar Pharmaceuticals to Present at the Wells Fargo Healthcare Conference 2018
RANCHO CUCAMONGA, Calif. , Aug. 29, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell , President, and Bill Peters , CFO will be presenting at the Wells Fargo Healthcare Conference on Thursday, September 6, 2018 at 9:10 a.m.
View HTML
Toggle Summary Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2018
Reports Net Revenues of $71.0 Million for the Three Months Ended June 30, 2018 RANCHO CUCAMONGA, Calif. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended June 30, 2018 .
View HTML

 

Copyright ©2019 Amphastar Pharmaceuticals, Inc.

Privacy      Terms & Conditions

This site is intended for residents of the United States